

Embargo until April 9, 2010, 11:45 am PDT

For Immediate Release

TSX Exchange Symbol: **RVX**

## Resverlogix Scientific Data Presented at ATVB Conference

April 9, 2010 (San Francisco, CA & Calgary, AB) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company’s lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology (ATVB) conference being held in San Francisco, California. The presentation titled “RVX-208, an Orally Active Small Molecule, Raises ApoA-I Production and HDL Levels in Human Trials and Also Reduces Plaque Numbers in a Mouse Model of Atherosclerosis” was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

Resverlogix’s oral small molecule therapy for the treatment of atherosclerosis is currently being studied in two parallel Phase 2 clinical trials. The first trial focuses on stable coronary artery disease patients, while the second trial examines patients with unstable acute coronary syndrome and includes the use of intravascular ultrasound (IVUS). Both of these studies are chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at the Cleveland Clinic.

Cardiovascular disease is the leading cause of death in the US and other developed nations costing the American health care system an estimated \$448.5 billion in 2008. According to the American Heart Association’s *Heart Disease & Stroke Statistics 2010* publication, approximately every 25 seconds an American will have a coronary event and approximately every minute, someone will die from such an event. A key underlying cause of cardiovascular disease is atherosclerosis, a build-up of plaque in the arteries often referred to as ‘hardening of the arteries’.

Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL), represents the body’s natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that within the atherosclerotic plaques of the vessel wall to the liver for processing. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibits progression and induces regression of atherosclerosis in animals and humans. Developing small molecules that increase ApoA-I would satisfy a vast unmet medical need.

### **About Resverlogix Corp.**

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer’s disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.’s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit [www.resverlogix.com](http://www.resverlogix.com).

*This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, stable Coronary Artery Disease, Acute Coronary Syndrome and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and*

*unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at [www.sedar.com](http://www.sedar.com). Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.*

**For further information please contact:**

Theresa Kennedy  
VP, Corporate Communications  
Resverlogix Corp.  
Phone: 604-538-7072  
Fax: 403-256-8495  
Email: [Theresa@resverlogix.com](mailto:Theresa@resverlogix.com)

Sarah Zapotichny  
Manager, Investor Relations  
Resverlogix Corp.  
Phone: 403-254-9252  
Fax: 403-256-8495  
Email: [Sarah@resverlogix.com](mailto:Sarah@resverlogix.com)